ECSP12011800A - Composición farmacéutica para bajar de peso y procedimiento para obtener la misma - Google Patents

Composición farmacéutica para bajar de peso y procedimiento para obtener la misma

Info

Publication number
ECSP12011800A
ECSP12011800A ECSP12011800A ECSP12011800A EC SP12011800 A ECSP12011800 A EC SP12011800A EC SP12011800 A ECSP12011800 A EC SP12011800A EC SP12011800 A ECSP12011800 A EC SP12011800A
Authority
EC
Ecuador
Prior art keywords
procedure
pharmaceutical composition
same
lower weight
orlistat
Prior art date
Application number
Other languages
English (en)
Inventor
Armenta María Elena García
Ochoa Víctor Guillermo Álvarez
Murillo Josefina Santos
Original Assignee
World Trade Imp Exp Wtie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by World Trade Imp Exp Wtie Ag filed Critical World Trade Imp Exp Wtie Ag
Publication of ECSP12011800A publication Critical patent/ECSP12011800A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe una composición farmacéutica para bajar de peso que comprende una mezcla de Orlistat y L-Carnitina como ingredientes activos, y un vehículo farmacéuticamente aceptable. Asimismo, se describe un procedimiento para obtener dicha composición donde se realiza una humectación y granulación húmeda del Orlistat que evita que se presenten problemas de pegado o escasa fluidez de este compuesto.
ECSP12011800 2009-09-18 2012-04-16 Composición farmacéutica para bajar de peso y procedimiento para obtener la misma ECSP12011800A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2009009971A MX342962B (es) 2009-09-18 2009-09-18 Composicion farmaceutica para bajar de peso y procedimiento para obtener la misma.

Publications (1)

Publication Number Publication Date
ECSP12011800A true ECSP12011800A (es) 2012-05-30

Family

ID=43758159

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011800 ECSP12011800A (es) 2009-09-18 2012-04-16 Composición farmacéutica para bajar de peso y procedimiento para obtener la misma

Country Status (8)

Country Link
EP (1) EP2478902A4 (es)
AR (1) AR078185A1 (es)
BR (1) BR112012006013A2 (es)
CO (1) CO6541522A2 (es)
EC (1) ECSP12011800A (es)
GT (1) GT201200079A (es)
MX (1) MX342962B (es)
WO (1) WO2011033356A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
IT1305308B1 (it) * 1999-03-26 2001-05-04 Biosint S P A Granulato ad alto contenuto di l-carnitina o alcanoil-l-carnitina,particolarmente adatto alla produzione di compresse per compressione
WO2003009840A1 (en) * 2001-07-24 2003-02-06 Lonza Ag Composition comprising at least one lipase inhibitor and carnitine
CN1546017A (zh) * 2003-11-30 2004-11-17 杨喜鸿 奥利司他的复方制剂
JP2006191830A (ja) * 2005-01-12 2006-07-27 Unitika Ltd 脂肪の蓄積を抑制する食品
TR200607613A2 (tr) * 2006-12-29 2008-07-21 NOBEL İLAÇ SAN.ve TiC.A.Ş. Lipaz inhibitörü içeren farmasötik formülasyonlar
SI2002825T1 (sl) * 2007-06-14 2013-10-30 Krka Farmacevtski sestavki, ki obsegajo orlistat
CN101224202A (zh) * 2007-12-26 2008-07-23 广州康采恩医药有限公司 减肥组合物

Also Published As

Publication number Publication date
GT201200079A (es) 2014-01-27
EP2478902A1 (en) 2012-07-25
AR078185A1 (es) 2011-10-19
MX342962B (es) 2016-06-07
WO2011033356A1 (es) 2011-03-24
BR112012006013A2 (pt) 2016-06-14
EP2478902A4 (en) 2014-05-14
CO6541522A2 (es) 2012-10-16
MX2009009971A (es) 2011-03-18

Similar Documents

Publication Publication Date Title
UY35040A (es) Pirrolopirimidinilamino-benzotiazolonas sustituidas
CO6720961A2 (es) Imidazopiridazinas sustituidas
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
UY33735A (es) Compuestos antivirales
NI201400070A (es) Compuestos de benzaldehído sustituidos y métodos para su uso en incrementar la oxigenación del tejido.
CO6460772A2 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CL2012001959A1 (es) Compuestos derivados del acido tiofeno-2-carboxilico, inhibidores de virus flaviviridae; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion viral por flaviviridae.
MX377553B (es) Composicion farmaceutica estable y metodos de uso de la misma.
UY30444A1 (es) Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
GT201200207A (es) Derivados de imidazopiridina como inhibidores de jak
CO6771409A2 (es) Acidos 1-bencilcicloalquilcarboxilicos sustituidos y su uso
CL2012002355A1 (es) Compuestos derivados de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina; composicion farmaceutica que los comprende; kit farmaceutico; y su uso como inhibidores de la integrasa del vih para el tratamiento de una enfermedad infecciosa del vih.
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
GT201400017A (es) Derivados de piridin-2 (1h) -ona como inhibidores de jak
CR20120317A (es) Derivados de 2-arimidazol heteroaromáticos como inhibidores de enzima pde10a
CO6470821A2 (es) Pirazinilpirazoles
EA201101596A1 (ru) Композиция для непрерывной доставки лекарственного средства, содержащая геополимерное связующее
BR112013004662B8 (pt) Composto, composição farmacêutica, usos de um composto, e método para preparar uma composição farmacêutica
NI201000189A (es) Formulación de medicamento sólido con liberación retardadas.
UY31780A (es) Fenoxibenzamidas sustituidas
CL2011001860A1 (es) Compuestos derivados de indol; procedimiento de preparacion de dichos compuestos; composicion y combinacion farmaceutica; y uso en el tratamiento del cancer.
EA201200616A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола
CR20110703A (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt(pkb)
CR20140007A (es) N-(6-((2r, 3s)-3,4-dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio) pirimidin-4-il)-3-metilacetidina-1-sulfonamida como modulador del receptor de quimiocina